Overview

• Net loss for Q1 widened and missed analyst estimates

• US life sciences automation firm's Q1 revenue grew 11%, beating analyst expectations

• Company reaffirmed full-year 2026 revenue and gross margin guidance

Outlook

• Company reaffirms 2026 total revenue guidance of $37 mln to $41 mln

• Company expects 30 to 38 Growth Direct system placements and at least 25 system validations in 2026

• Company maintains 2026 gross margin percentage guidance of about 20%, with Q4 exit rate in mid-20% range

Result Drivers

• CONSUMABLE SALES - Strong consumable revenue contributed to nearly 30% growth in recurring revenue, reflecting increased utilization of installed systems

• SYSTEM PLACEMENTS - Higher number of Growth Direct system placements supported product revenue growth

• SERVICE REVENUE DECLINE - Lower validation activity led to a decrease in service revenue

Company press release: ID:nGNX1xBrfB

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Beat	$8 mln	$7.60 mln (4 Analysts)
Q1 EPS		-$0.31
Q1 Net Income	Miss	-$14.30 mln	-$10.93 mln (3 Analysts)
Q1 Operating Expenses		$14.20 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Rapid Micro Biosystems, Inc is $8.00, about 210.1% above its May 12 closing price of $2.58

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.